Dermorphin vs Leuprolide
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinSexual Health & Libido
Leuprolide- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- SubQ, IM
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- Frequency
- Not established
- Per depot schedule
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Stacks With
- —
- —